March 12, 2010
Corporate

PDF (1.48MB)

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo Announces Second Mid-term Business Management Plan (FY 2010-2012)

Tokyo, Japan, March 12, 2010 - Daiichi Sankyo Company Limited (hereafter; Daiichi Sankyo) today announced that it will launch its Second Mid-term Business Management Plan, effective April 2010. The plan will be in effect through fiscal year 2012.

The current mid-term plan, which began in April 2007 and ends on March 31, 2010, focused on broadening Daiichi Sankyo's foundation for growth by optimizing the operational synergies of the two companies, Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. The plan also focused on accelerating the company's globalization initiatives in keeping with its vision of becoming a "Global Pharma Innovator" by 2015.

The Second Mid-term Business Management Plan will prioritize creating more innovative products while pushing ahead with a "Hybrid Business Model" that emphasizes vaccines, established pharmaceuticals, and OTC products to address market and customer diversity. For its new plan, Daiichi Sankyo has outlined the following growth targets, which exceed the global market average. The foundation of these targets is the strength of the company's diverse lineup of pharmaceutical products.

Overview of Second Mid-term Business Management Plan

I. Fiscal 2012 Consolidated Targets


II. Basic Policies of Second Mid-term Business Management Plan

1. Regional Business Strategies
 
(1) Japan
  • Innovative Pharmaceuticals
  • Maximize sales of the olmesartan franchise centering on the antihypertensive agent Rezaltas while launching laninamivir, a long-acting neuraminidase inhibitor for the treatment of influenza, memantine, a treatment of Alzheimer's type Dementia, and other high-potential products to generate earnings and sustainable growth in this core Group business
  • Vaccines
  • Reinforce and expand the prophylactic vaccine business in which medical needs are strong
  • Established Pharmaceuticals
  • Address diverse market needs in a changing operating climate by establishing Daiichi Sankyo Espha Co., Ltd. in April 2010
  • OTC
  • Promote OTC operations by focusing on consumers' self-medication needs

 

 

(2) United States
  • Maximize the olmesartan franchise and position the antiplatelet agent Effient as the first-choice treatment for acute coronary syndrome patients with percutaneous coronary interventions to achieve combined Group sales in the US of $3.5 billion and a 1% share of the prescription drugs market

 

 

(3) Europe
  • Maximize the olmesartan franchise and Efient sales and bolster in-house sales and marketing capabilities to generate combined Group sales in Europe of 1.2 billion euros

 

 

(4) ASCA (in-house term for markets outside of Japan, US and Europe)
  • Expand the olmesartan franchise, launch and build sales of prasugrel, and cultivate synergies with Ranbaxy to grow at a faster rate than Japan, the US, and Europe to generate sales of at least ¥150 billion

 

 

2. R&D Strategies

 

 

(1) Enhance competitiveness in priority areas, including oncology and cardiovascular-metabolics, where significant unmet medical needs remain
  • Draw on R&D foundations to reinforce research in oncology and cardiovascular- metabolics areas towards 2015

 

 

(2) Promote implementation of international clinical studies
  • Undertake simultaneous global development for an oral factor Xa inhibitor edobaxan and other drugs

 

 

(3) Discover new lines of research through open innovation

 

 

3. Global CSR and Cultivating Personnel

 

 

(1) Harmonize with society and the global environment by enhancing employee diversity and valuing consideration of others as a company that supports humanity and health

 

 

(2) Continue to build a corporate culture in which all our employees are professional, responsible and accountable, and where they feel both satisfaction and challenge from their work and are able to demonstrate their abilities and talents

 

III. Shareholder Returns

Balance funding for growth investments and internal reserves, maintaining stable dividends while generating shareholder returns in-line-with results

 

 

Please see the appended materials for details.
>> Archive, Information Meeting Material

 

 

 

End

 

Back to index